ClinicalTrials.gg
RecruitingNCT06033950FINALITY-HFUpdated Jul 10, 2026

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

A Phase 3 interventional study of Finerenone and Placebo in Heart Failure, sponsored by Colorado Prevention Center. Recruiting at 176 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Colorado Prevention Center · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies testing finerenone in Heart Failure — 16 open to participants now, 17 under way, 8 of them phase 3. finerenone · Heart Failure.

Planned enrollment
4th of 23
2,600 · median 120
Started
2024
with 4 others
Phase 3
9 of 23
8 open now
Primary completion
2026-08
later than 1 of 16 live
Registered
10th of 23
by date
Lead sponsor
3 of 23
Colorado Prevention Center

Among the 23 studies testing finerenone in Heart Failure, this one is the 4th largest by planned enrollment, is one of 5 that started in 2024, is one of 9 in phase 3, reaches primary completion later than 1 of the 16 other live ones, and was the 10th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 23 studies testing finerenone in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing finerenone in Heart Failure, or all of them as a file.
02

Study summary

Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).

Read the detailed description

This is an international, randomized, double-blind, placebo-controlled trial of finerenone for the treatment of heart failure patients with reduced ejection fraction.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Reduced ejection fraction
  • Symptomatic heart failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide electronic or written , either personally or through a legally authorized representative, as permitted by local regulations
  • Age ≥18 years or legal age of majority if >18 years in the participant's country of residence
  • Symptomatic HFrEF per protocol defined criteria
  • Not on sMRA due to history of intolerance, , or ineligibility for treatment
  • Negative pregnancy test and agreement to use adequate during trial (female participants only)

Exclusion criteria

Exclusion Criteria:

  • Treatment with non-steroidal MRA (nsMRA)
  • Documented prior history of severe hyperkalemia in the setting of MRA use
  • \< 25 mL/min/1.73m² and / or potassium > 5.0 mmol/L
  • Acute myocardial infarction, coronary revascularization, valve replacement/repair, or implantation of a cardiac resynchronization therapy device within 30 days or planned
  • Prior or planned heart transplant
  • Hemodynamically significant (severe) uncorrected primary cardiac valvular disease considered by the investigator to be the primary cause of heart failure
  • Symptomatic bradycardia or second- or third-degree heart block without a pacemaker
  • Cardiomyopathy due to known acute inflammatory heart disease, infiltrative diseases, accumulation diseases, muscular dystrophies, cardiomyopathy with reversible causes, hypertrophic obstructive cardiomyopathy, complex congenital heart disease, or pericardial constriction
  • Probable alternative cause of participant's HF
  • Concomitant systemic therapy with potent cytochrome P450 isoenzyme 3A4 () inhibitors, or moderate or potent CYP3A4 inducers
  • Known to the IP (active substance or )
  • Any other condition or therapy which would make the participant unsuitable for the study
  • Concurrent or previous participation in another interventional clinical study using an agent within 30 days prior to randomization
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,600 participants (estimated)

Study arms

  • Experimental
    Finerenone

    Drug: Finerenone

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Oral finerenone.

  • DrugPlacebo

    Matching oral placebo.

06

What researchers measure

Primary outcomes

  1. Time to first occurrence of cardiovascular (CV) death or HF event.

    \- Time to first CV death or HF event with finerenone compared to placebo.

    Time frame: Ongoing, up to ~30 months

  2. Number of serious adverse events

    \- Serious adverse events (excluding efficacy endpoints) with finerenone compared to placebo.

    Time frame: Ongoing, up to ~30 months

  3. Number of adverse events leading to discontinuation of study drug.

    \- Number of adverse events leading to discontinuation of investigational product with finerenone compared to placebo.

    Time frame: Ongoing, up to ~30 months

Secondary outcomes

  1. Timing and occurrence of total CV deaths and HF events

    \- Timing and occurrence of total (first and subsequent) events of CV death and HF events and CV deaths with finerenone compared to placebo.

    Time frame: Ongoing, up to ~30 months

  2. Timing and occurrence of total HF events

    Timing and occurrence of total (first and recurrent) HF events with finerenone compared to placebo.

    Time frame: Ongoing, up to ~30 months

  3. Change in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) from baseline to Month 6.

    \- Change in KCCQ-TSS with finerenone compared to placebo.

    Time frame: 180 days

  4. Time to CV death.

    \- Time to CV death with finerenone compared to placebo.

    Time frame: Ongoing, up to ~30 months

  5. Time to all-cause death.

    \- Time to all-cause mortality with finerenone compared to placebo.

    Time frame: Ongoing, up to ~30 months

07

Study locations

176 of 176 sites recruiting
  • FIN-10004 Fairhope, AL Investigational Site
    Fairhope, Alabama 36532, United States
    Recruiting
  • Phoenix, AZ Investigative Site FIN-10115
    Phoenix, Arizona 85006, United States
    Recruiting
  • FIN-10401, Yuma, AZ
    Yuma, Arizona 85365, United States
    Recruiting
  • Chula Vista, CA Investigative Site FIN-10419
    Chula Vista, California 91910, United States
    Recruiting
  • Chula Vista, CA Investigative Site FIN-10111
    Chula Vista, California 91911, United States
    Recruiting
  • FIN-10407, Northridge, CA
    Northridge, California 91324, United States
    Recruiting
  • FIN-10412, Orange, CA
    Orange, California 92866, United States
    Recruiting
  • FIN-10070, Pamona, CA
    Pomona, California 91767, United States
    Recruiting
  • FIN-10024, Sacramento, CA
    Sacramento, California 95816, United States
    Recruiting
  • FIN-10406, San Diego, CA
    San Diego, California 91127, United States
    Recruiting
  • San Diego, CA Investigative Site FIN-10420
    San Diego, California 92111, United States
    Recruiting
  • FIN-10075 San Diego, CA Investigational Site
    San Diego, California 92243, United States
    Recruiting
  • San Francisco, CA Investigative Site FIN-10023
    San Francisco, California 94118, United States
    Recruiting
  • FIN-10423, Sherman Oaks, CA
    Sherman Oaks, California 91403, United States
    Recruiting
  • FON-10409, Tarzana, CA
    Tarzana, California 91356, United States
    Recruiting
  • FIN-10109, Van Nuys, CA
    Van Nuys, California 91405, United States
    Recruiting
  • FIN-10408, West Covina, CA
    West Covina, California 91790, United States
    Recruiting
  • FIN-10013, West Hills, CA
    West Hills, California 91307, United States
    Recruiting
  • FIN-10110, Aurora, CO
    Aurora, Colorado 80012, United States
    Recruiting
  • FIN-10001, Aurora, CO
    Aurora, Colorado 80045, United States
    Recruiting
  • Bradenton, FL Investigative Site FIN-10125
    Bradenton, Florida 34209, United States
    Recruiting
  • FIN-10104, Hialeah, FL
    Hialeah, Florida 33012, United States
    Recruiting
  • FIN-10028, Jacksonville, FL
    Jacksonville, Florida 32209, United States
    Recruiting
  • FIN-10105, Miami, FL
    Miami, Florida 33135, United States
    Recruiting
  • FIN-10113, Miramar, FL
    Miramar, Florida 33027, United States
    Recruiting
  • FIN-10019, Peoria, IL
    Peoria, Illinois 61603, United States
    Recruiting
  • FIN-10064, Merrillville, IN
    Merrillville, Indiana 46410, United States
    Recruiting
  • Cynthiana, KY Investigative Site FIN-10124
    Cynthiana, Kentucky 41031, United States
    Recruiting
  • FIN-10080, Lexington, KY
    Lexington, Kentucky 40503, United States
    Recruiting
  • Lexington, KY Investigative Site FIN-10118
    Lexington, Kentucky 40536, United States
    Recruiting
  • FIN-10086, Louisville, KY
    Louisville, Kentucky 40205, United States
    Recruiting
  • Louisville, KY Investigative Site FIN-10417
    Louisville, Kentucky 40205, United States
    Recruiting
  • FIN-10079, Paducah, KY
    Paducah, Kentucky 42003, United States
    Recruiting
  • FIN-10030, Baton Rouge, LA
    Baton Rouge, Louisiana 70808, United States
    Recruiting
  • FIN-10106, Hammond, LA
    Hammond, Louisiana 70403, United States
    Recruiting
  • FIN-10090, West Monroe, LA
    West Monroe, Louisiana 71291, United States
    Recruiting
  • Minneapolis, MN Investigative Site FIN-10035
    Minneapolis, Minnesota 55417, United States
    Recruiting
  • FIN-10002 Kansas City, MO Investigational Site
    Kansas City, Missouri 64111, United States
    Recruiting
  • FIN-10318, Charlotte, NC
    Charlotte, North Carolina 28207, United States
    Recruiting
  • Greenville, NC Investigative Site FIN-10122
    Greenville, North Carolina 27834, United States
    Recruiting
  • FIN-10081, Akron, OH
    Akron, Ohio 44304, United States
    Recruiting
  • FIN-10119, Centerville, OH
    Centerville, Ohio 45459, United States
    Recruiting
  • FIN- 10112, Cincinnati, OH
    Cincinnati, Ohio 45219, United States
    Recruiting
  • Orangeburg, SC Investigative Site FIN-10433
    Orangeburg, South Carolina 29118, United States
    Recruiting
  • FIN-10015 Austin, TX Investigational Site
    Austin, Texas 78705, United States
    Recruiting
  • FIN-10404, Denison, TX
    Denison, Texas 75020, United States
    Recruiting
  • FIN-10085, Houston, TX
    Houston, Texas 77030, United States
    Recruiting
  • Tyler, TX Investigative Site FIN-10422
    Tyler, Texas 75702, United States
    Recruiting
  • FIN-10405, Layton, UT
    Layton, Utah 84041, United States
    Recruiting
  • FIN-10053, Burlington, VT
    Burlington, Vermont 05401, United States
    Recruiting
  • FIN-10402, Norfolk, VA
    Norfolk, Virginia 23510, United States
    Recruiting
  • FIN-10093, Richmond, VA
    Richmond, Virginia 23298-5051, United States
    Recruiting
  • Salem, VA Investigative Site FIN-10048
    Salem, Virginia 24153, United States
    Recruiting
  • Milwaukee, WI Investigative Site FIN-10428
    Milwaukee, Wisconsin 53215, United States
    Recruiting
  • Lanus, Buenos Aires Investigative Site FIN-20024
    Lanus, Buenos Aires 1824, Argentina
    Recruiting
  • Rosario, Santa Fe Investigative Site FIN-20022
    Rosario, Santa Fe Province 2300, Argentina
    Recruiting
  • Buenos Aires Investigative Site FIN-20031
    Buenos Aires, 1425, Argentina
    Recruiting
  • Córdoba Investigative Site FIN-20025
    Córdoba, 5000, Argentina
    Recruiting
  • Córdoba Investigative Site FIN-20030
    Córdoba, 5000, Argentina
    Recruiting
  • San Juan, San Juan Investigative Site FIN-20020
    San Juan, J5402DIL, Argentina
    Recruiting
  • San Juan, San Juan Investigative Site FIN-20021
    San Juan, J5402DIL, Argentina
    Recruiting
  • FIN-21063, Rio Branco, Acre
    Rio Branco, Acre 69915-030, Brazil
    Recruiting
  • FIN-21078, Maceió, Alagoas
    Maceió, Alagoas 57051-160, Brazil
    Recruiting
  • FIN-21072 Salvador, Bahia - BA
    Salvador, Bahia - BA 40290-000, Brazil
    Recruiting
  • Fortaleza, Ceará Investigative Site'FIN-21076
    Fortaleza, Ceará 60430275, Brazil
    Recruiting
  • Fortaleza, Ceará Investigative Site FIN-21055
    Fortaleza, Ceará 60864-190, Brazil
    Recruiting
  • FIN-21032, Salvador, Bahia
    Salvador, Estado de Bahia 40050-410, Brazil
    Recruiting
  • FIN-21028, Brasilia, Distrito Federal
    Brasília, Federal District 70390-700, Brazil
    Recruiting
  • FIN-21053, Aparecida de Goiânia, Goiás
    Aparecida de Goiânia, Goiás 74936-600, Brazil
    Recruiting
  • FIN-21003 Goiania, Goias Investigational Site
    Goiânia, Goiás 74453-200, Brazil
    Recruiting
  • Belo Horizonte, Minas Gerais
    Belo Horizonte, Minas Gerais 30110-934, Brazil
    Recruiting
  • FIN-21071, Belo Horizonte, Minas Gerais
    Belo Horizonte, Minas Gerais 30150-320, Brazil
    Recruiting
  • FIN-21051, Belo Horizonte, Minas Gerais
    Belo Horizonte, Minas Gerais 30220-140, Brazil
    Recruiting
  • Belo Horizonte, Minas Gerais Investigative Site FIN-21079
    Belo Horizonte, Minas Gerais 30220-330, Brazil
    Recruiting
  • FIN-21013, Belo Horizonte, Minas Gerais
    Belo Horizonte, Minas Gerais 30441-070, Brazil
    Recruiting
  • FIN-21056, Curitiba, Paraná
    Curitiba, Paraná 80060-900, Brazil
    Recruiting
  • FIN-21047, Londrina, Paraná
    Londrina, Paraná 86.038-350, Brazil
    Recruiting
  • FIN-21021, Recife, Pernambuco
    Recife, Pernambuco 50100-040, Brazil
    Recruiting
  • Recife, Pernambuco Investigative Site FIN-21086
    Recife, Pernambuco 51.110-160, Brazil
    Recruiting
  • FIN-21061, Recife, Pernambuco
    Recife, Pernambuco 52010-075, Brazil
    Recruiting
  • Teresina, Piaui Investigative Site FIN-21050
    Teresina, Piauí 64001-450, Brazil
    Recruiting
  • FIN-21001, Recife, Recife
    Recife, Recife 50720-110, Brazil
    Recruiting
  • FIN-21016, Rio De Janeiro, Rio De Janeiro
    Rio de Janeiro, Rio de Janeiro 20551-030, Brazil
    Recruiting
  • FIN-21014, Rio de Janeiro, Rio de Janeiro
    Rio de Janeiro, Rio de Janeiro 22240-006, Brazil
    Recruiting
  • FIN-21024, Natal, Rio Grande do Norte
    Natal, Rio Grande do Norte 5902050, Brazil
    Recruiting
  • FIN-21008, Caxias do Sul, Rio Grande do Sul
    Caxias do Sul, Rio Grande do Sul 95070-560, Brazil
    Recruiting
  • FIN-21019, Porto Alegre, Rio Grande do Sul
    Porto Alegre, Rio Grande do Sul 90840-440, Brazil
    Recruiting
  • FIN-21007, Joinville, Santa Catarina
    Joinville, Santa Catarina 89200-000, Brazil
    Recruiting
  • FIN-21058, Aracaju, Sergipe
    Aracaju, Sergipe 49055-210, Brazil
    Recruiting
  • FIN-21004 Braganca Paulista, Sao Paulo
    Bragança Paulista, São Paulo 12916542, Brazil
    Recruiting
  • Campinas, São Paulo Investigative Site' FIN-21083
    Campinas, São Paulo 13083-190, Brazil
    Recruiting
  • FIN-21068, Guarulhos, São Paulo
    Guarulhos, São Paulo 07197-000, Brazil
    Recruiting
  • FIN-21005, Itaquera, São Paulo
    Itaquera, São Paulo 08270-120, Brazil
    Recruiting
  • FIN-21010, Osasco, São Paulo
    Osasco, São Paulo 06013-070, Brazil
    Recruiting
  • FIN-21011, Presidente Prudente, São Paulo
    Presidente Prudente, São Paulo 19050-680, Brazil
    Recruiting
  • FIN-21043, Santo André, São Paulo
    Santo André, São Paulo 09090790, Brazil
    Recruiting
  • São Carlos, São Paulo Investigative Site FIN-21075
    São Carlos, São Paulo 13566-448, Brazil
    Recruiting
  • São José dos Campos, São Paulo Investigative Site'FIN-21081
    São José dos Campos, São Paulo 12243000, Brazil
    Recruiting
  • FIN-21074, São Paulo, São Paulo
    São Paulo, São Paulo 01229-010, Brazil
    Recruiting
  • FIN-21037, São Paulo, São Paulo
    São Paulo, São Paulo 01323-001, Brazil
    Recruiting

Showing the first 100 of 176 sites across 14 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Aug 2026, 24 months after the start.

Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 24 months is below that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2023
First posted
Sep 13, 2023
StartActual
Aug 20, 2024
Primary completionEst.
Aug 2026
CompletionEst.
Jan 2028
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06033950
Lead sponsor
Colorado Prevention Center
Collaborators
St. Luke's Hospital, Kansas City, Missouri, Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Responsible party
Sponsor
First posted
Sep 13, 2023
Start date
Aug 20, 2024
Primary completion
Aug 2026 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jul 10, 2026

Study contacts

Marc Bonaca
Contact
info@cpcmed.org
(303) 860-9900

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion